ARSB（arylsulfatase B）基因编码芳基硫酸酯酶B，这是一种溶酶体酶，主要功能是分解糖胺聚糖（GAGs）中的硫酸酯基团，特别是硫酸皮肤素和硫酸软骨素。该酶在溶酶体中发挥作用，帮助降解这些大分子，防止它们在细胞内积累。ARSB属于硫酸酯酶基因家族，该家族成员均含有高度保守的硫酸酯酶活性位点，并依赖钙离子进行催化。ARSB的功能缺陷会导致黏多糖贮积症VI型（Maroteaux-Lamy综合征），这是一种罕见的遗传病，表现为骨骼异常、心脏问题、角膜混浊和生长迟缓，原因是GAGs在组织中异常积累。ARSB基因突变可能引起酶活性降低或完全丧失，进而影响GAGs的正常代谢。过表达ARSB的研究较少，但理论上可能加速GAGs的降解，可能对某些代谢异常疾病有潜在治疗作用。降低表达或功能缺失则直接导致黏多糖贮积症VI型。ARSB与其他硫酸酯酶家族成员（如ARSA、ARSE）在结构和功能上相似，但底物特异性不同。该基因位于人类5号染色体（5q14.1），其活性受pH值和溶酶体环境调控。诊断黏多糖贮积症VI型通常通过检测尿液GAGs水平或ARSB酶活性，基因测序可确认突变位点。治疗上，酶替代疗法（如galsulfase）可用于补充缺失的酶活性。研究还发现ARSB可能与癌症进展有关，因其参与细胞外基质重塑，但具体机制尚不明确。

该基因编码芳基硫酸酯酶b属于硫酸家庭。的芳基硫酸酯酶乙同二聚体水解N-乙酰-D-半乳糖胺，chondriotin硫酸盐和硫酸皮肤素的硫酸基。该蛋白为对象的溶菌酶。黏多糖贮积症VI型是芳基硫酸酯酶B的缺乏两个可变剪接的转录产生一种常染色体隐性溶酶体贮积症变种编码不同的亚型已经发现了这种基因。 [由RefSeq的，2008年7月提供]

The ARSB gene encodes arylsulfatase B, a lysosomal enzyme that plays a critical role in the catabolism of glycosaminoglycans (GAGs) by catalyzing the removal of sulfate ester groups, particularly from dermatan sulfate and chondroitin sulfate. As a member of the sulfatase gene family, this enzyme possesses a highly conserved active site and relies on calcium ions for its catalytic activity, operating within the acidic environment of the lysosome to prevent the intracellular accumulation of these large macromolecules. Located on the long arm of human chromosome 5 at position 5q14.1, ARSB exhibits substrate specificity that distinguishes it from other family members such as ARSA and ARSE, despite their structural and functional similarities. Loss-of-function mutations in ARSB, which may result in reduced or absent enzyme activity, lead to Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome), a rare autosomal recessive disorder characterized by the pathological accumulation of GAGs in tissues, resulting in skeletal dysplasia, cardiac complications, corneal clouding, and growth retardation. Diagnosis of this condition typically involves assessing urinary GAG levels or measuring ARSB enzyme activity, with genetic sequencing confirming specific mutations, while enzyme replacement therapy using agents like galsulfase serves as a primary therapeutic intervention to restore metabolic balance. Although research on the overexpression of ARSB is limited, theoretical models suggest that enhanced expression could accelerate GAG degradation and potentially offer therapeutic benefits for certain metabolic disorders. Furthermore, emerging evidence indicates that ARSB may be implicated in cancer progression through its involvement in extracellular matrix remodeling, although the precise molecular mechanisms underlying this association remain to be fully elucidated.

Loading comments...